Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SARS-CoV-2 recombinant protein vaccine monovalent B.1.351 Alternative Exploratory Formulation 2
- Development stage
- Unknown
- Lead developer
- Novavax
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
This is a monovalent recombinant protein subunit vaccine candidate developed by Sanofi and GSK, specifically targeting the B.1.351 (Beta) variant of SARS-CoV-2. It utilizes Sanofi's baculovirus expression system to produce a prefusion-stabilized soluble spike (S) protein (preS dTM) and is formulated with GSK's AS03 adjuvant system. The Alternative Exploratory Formulation 2 refers to a specific experimental dosage (10 µg of antigen) tested during Phase 2 clinical trials (such as VAT00002) to optimize the immune response against emerging variants. The vaccine works by inducing neutralizing antibodies and T-cell responses against the viral spike protein, preventing viral entry into host cells.
- Brand names
- Vidprevtyn Beta
- Other names
- Sanofi-GSK Beta vaccineVAT00002 Formulation 2VAT-00002 Formulation 2VAT 00002 Formulation 2
02
Targets
SARS-CoV-2 spike glycoprotein (prefusion-stabilized)SARS-CoV-2 spike
Beyond the preview
Go deeper on SARS-CoV-2 recombinant protein vaccine monovalent B.1.351 Alternative Exploratory Formulation 2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SARS-CoV-2 recombinant protein vaccine monovalent B.1.351 Alternative Exploratory Formulation 2.